CSE AIML | OTCQB AIMLF | FWB 42FB
PRESS RELEASE

AI/ML Innovations Inc. Announces Proposed Private Placement of Convertible Debentures

March 12, 2026

TORONTO, ON / March 12, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FSE:42FB) is pleased to announce that it is proposing to complete a non-brokered private placement (the "Offering") pursuant to which the Company will issue convertible debentures ("Debentures") in the principal amount of up to $3,000,000. The Debentures may be converted into units of the Company ("Units") at the option of the holder of the Debentures at any time at a conversion price of $0.05 per Unit, with each Unit being comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant"). Subject to the anti-dilution provisions that will be contained in the certificates governing the terms of the Warrants, each whole Warrant shall be exercisable to acquire one Common Share at a price of $0.15 for a period of 36 months from the date of issuance of the Warrants. The Debentures will bear interest at a rate of 10% per annum that accrues and is payable on the earlier of maturity or conversion, with accrued/unpaid interest also being convertible into Units under the same terms. The Debentures shall mature on the date that is three years following the date of issuance thereof.

The Offering remains subject to various closing conditions, including the approval of the Canadian Securities Exchange.

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.

About AI/ML Innovations Inc.

AI/ML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Our proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights-supporting earlier diagnosis, personalized treatment, and more effective care. AIML's shares trade on the Canadian Securities Exchange (CSE:AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).

For detailed information please see AIML's website or the Company's filed documents at www.sedarplus.ca.

For further information, please contact:

Blake Fallis
(778) 405-0882
blake@aiml.health

Disclaimer for Forward-Looking Information

This news release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts are forward-looking statements. Such forward-looking statements and forward-looking information specifically include, but are not limited to, statements that relate to the anticipated terms and proposed completion of the Offering, and the receipt of all applicable regulatory consents in connection therewith. There is no assurance that the proposed Offering will be completed upon terms as presently proposed or at all.

Statements contained in this release that are not historical facts are forward-looking statements that involve various risks and uncertainty affecting the business of the Company. Such statements can generally, but not always, be identified by words such as "expects", "plans", "anticipates", "intends", "estimates", "forecasts", "schedules", "prepares", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. All statements that describe the Company's plans relating to operations and potential strategic opportunities are forward-looking statements under applicable securities laws. These statements address future events and conditions and are reliant on assumptions made by the Company's management, and so involve inherent risks and uncertainties, as disclosed in the Company's periodic filings with Canadian securities regulators. As a result of these risks and uncertainties, and the assumptions underlying the forward-looking information, actual results could materially differ from those currently projected, and there is no representation by the Company that the actual results realized in the future will be the same in whole or in part as those presented herein. The Company disclaims any intent or obligation to update forward-looking statements or information except as required by law. Readers are referred to the additional information regarding the Company's business contained in the Company's reports filed with the securities regulatory authorities in Canada. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that could cause actions, events or results not to be as anticipated, estimated or intended. For more information on the Company and the risks and challenges of its business, investors should review the Company's filings that are available at www.sedar.com.

The Company provides no assurance that forward-looking statements and information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements or information. Accordingly, readers should not place undue reliance on forward-looking statements or information. The Company does not undertake to update any for-ward looking statements, other than as required by law.

Read More

March 12, 2026
AI/ML Innovations Inc. Announces Proposed Private Placement of Convertible Debentures
Read More
February 24, 2026
Neural Cloud Enters Distribution Agreement with Intelimed to Expand into Latin America
Read More
February 12, 2026
AIML Subsidiary NeuralCloud Signs Non-Binding Agreement with Movesense to Pilot AI-Powered ECG and Holter Reporting
Read More
February 10, 2026
Neural Cloud Retains Commission Wolf to Accelerate U.S. Commercial Expansion
Read More
January 28, 2026
AIML Appoints Dr. Paul Dorian as Medical Innovation Architect and Head of the Medical Advisory Board
Read More
January 20, 2026
AIML subsidiary NeuralCloud Collaborates with Movesense to Expand Bundled ECG Solutions for Clinical and Wellness Markets
Read More
January 8, 2026
AIML subsidiary NeuralCloud Solutions Inc., Signs Non-Binding Commercial Term Sheet with Lakeshore Cardiology to Deploy CardioYield™ for AI-Powered Holter Analysis
Read More
January 7, 2026
AIML Appoints Erik Suokas as Chief Operating Officer to Accelerate Commercial Execution and Operational Scale
Read More
December 30, 2025
AIML Announces the Conclusion of Consulting Agreement and Leadership Transition for President & Chief Commercial Officer
Read More
December 16, 2025
Join AIML’s Live Shareholder Update with Chairman & CEO Paul Duffy
Read More
December 9, 2025
AIML subsidiary NeuralCloud Solutions Signs Commercial Term Sheet with Culminate H Labs to Deploy MaxYield™ and Insight360™ into INTRINSICA's DNA-Guided Biofeedback Wellness Ecosystem
Read More
December 2, 2025
AIML subsidiary NeuralCloud Enters Pilot with Cornerstone Physiotherapy to Deploy MaxYield™ and Insight360™ for Elite Athlete Cardiac Performance Testing
Read More
November 26, 2025
AIML subsidiary NeuralCloud Signs Commercial Term Sheet with Equimetrics to Deploy MaxYield™ and CardioYield™ across Equine Cardiac Monitoring Platforms
Read More
November 24, 2025
AIML subsidiary Neural Cloud begins pilot at SickKids to Advance AI-Enabled Pediatric Cardiac Care
Read More
November 11, 2025
AI/ML Innovations Inc. Announces Grant of U.S. Patent Protecting Core ECG Signal-Processing Architecture
Read More
November 4, 2025
AIML Subsidiary NeuralCloud Solutions Engages Lonacas Consultants to Lead Regulatory Submission for CardioYield™ in Jamaica
Read More
October 21, 2025
AIML Subsidiary NeuralCloud Solutions Commencing Pilot with Canadian Cardiology Clinic to Advance AI-Powered ECG Reporting
Read More
October 15, 2025
AIML Subsidiary NeuralCloud Solutions and Heartdent Center Ltd. Launch Pilot Project to Advance Cardiac Care in Jamaica
Read More
October 7, 2025
AIML Subsidiary NeuralCloud Solutions and Toronto Heart Centre Launch a Pilot Program to Test AI-Powered Holter ECG Reporting
Read More
September 30, 2025
AIML and BC Brain Wellness Program Launch Pilot to Explore the Heart–Brain Connection
Read More
September 23, 2025
AIML Announces Closing of Oversubscribed Private Placement
Read More
September 4, 2025
AIML Announces Proposed Private Placement
Read More
August 21, 2025
AIML Announces SEDAR Filing
Read More
August 8, 2025
AIML Innovations Closes Quantum Sciences Ltd. Restructuring
Read More
June 10, 2025
AIML Strengthens IP Portfolio with Provisional Patents for AI Driven ECG Signal Processing
Read More
June 3, 2025
AIML Subsidiary Neural Cloud Signs LOI with Circular Health to License MaxYield™ ECG Signal-Processing
Read More
May 22, 2025
AIML Establishes Innovation Committee, Appoints Dr. Drew Dundas as Chair
Read More
May 20, 2025
AIML Establishes Medical Advisory Board to Drive AI Powered ECG Signal Processing Innovation
Read More
May 15, 2025
AIML Hits Key Regulatory Benchmark with 510(k) Filing for MaxYield™ Signal Enhancement Platform
Read More
May 5, 2025
AIML Innovations Appoints Political Strategist and Public Affairs Leader, Michael Diamond, to Board of Directors
Read More
April 25, 2025
AIML Innovations Announces Departure of Tim Daniels from Board of Directors
Read More
April 25, 2025
AIML Optimizes Quantum Sciences Acquisition to Drive Growth & Strategic Focus
Read More
April 22, 2025
AIML Innovations Appoints Jared Adelstein to Board of Directors
Read More
April 15, 2025
AIML Announces Closing of Oversubscribed Private Placement
Read More
April 7, 2025
AIML Updates Terms of Proposed Private Placement Announced
Read More
April 4, 2025
AIML Announces Proposed Private Placement
Read More
January 9, 2025
AI/ML Innovations Inc. Welcomes Industry Trailblazers to Board of Directors
Read More
January 23, 2025
AI/ML Innovations Inc. Appoints Dr. Alan Rabinowitz as Chief Medical Officer and Director of Medical Partnerships
Read More
January 28, 2025
Andrea Ruth Joins AI/ML Innovations as Head of Quality, Clinical, and Regulatory Affairs
Read More
February 20, 2025
Key Updates to Upcoming Annual and Special Meeting
Read More
March 14, 2025
AIML Aligns Leadership for Growth and Shareholder Value Creation
Read More
March 21, 2025
AIML Continues to Streamline for the Future and Moves Beyond Tech2Heal
Read More